Stanford's Donald Kennedy: The View From the University

For Stanford president Donald Kennedy, the last year has brought trying times. In the last 12 months, Stanford has investigated one of its professors for scientific misconduct, battled community groups opposed to the construction of two new research buildings (The Scientist, November 28, 1988, page 1), and suffered a mutiny by scientists in the Center for International Security and Arms Control over the control of academic appointments. Kennedy believes that some of these incidents are symptom

Written byMarcia Barinaga
| 10 min read

Register for free to listen to this article
Listen with Speechify
0:00
10:00
Share

Kennedy believes that some of these incidents are symptoms of deeper problems facing university scientists - and science itself - in the United States, problems that range from widespread scientific illiteracy to increasing demands on researchers' time. And the 57-year-old biologist and university president has been concerned enough about these issues to become a peripatetic and tireless spokesman for science.

Stanford's president has a long history of both interest in science policy and ties to Stanford. He arrived at the university in 1960 as an assistant professor in the department of biological sciences and conducted research on the neurobiology of behavior for the next 17 years. Along the way, he was elected to the National Academy of Sciences, served as chairman of biological sciences and later of Stanford's human biology program, and established a reputation in national science policy circles. In 1976, he was a senior consultant to the federal ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to digital editions of The Scientist, as well as TS Digest, feature stories, more than 35 years of archives, and much more!
Already a member? Login Here

Meet the Author

Published In

Share
February 2026

A Stubborn Gene, a Failed Experiment, and a New Path

When experiments refuse to cooperate, you try again and again. For Rafael Najmanovich, the setbacks ultimately pushed him in a new direction.

View this Issue
Human-Relevant In Vitro Models Enable Predictive Drug Discovery

Advancing Drug Discovery with Complex Human In Vitro Models

Stemcell Technologies
Redefining Immunology Through Advanced Technologies

Redefining Immunology Through Advanced Technologies

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Beckman Coulter Logo
Conceptual multicolored vector image of cancer research, depicting various biomedical approaches to cancer therapy

Maximizing Cancer Research Model Systems

bioxcell

Products

Sino Biological Logo

Sino Biological Pioneers Life Sciences Innovation with High-Quality Bioreagents on Inside Business Today with Bill and Guiliana Rancic

Sino Biological Logo

Sino Biological Expands Research Reagent Portfolio to Support Global Nipah Virus Vaccine and Diagnostic Development

Beckman Coulter

Beckman Coulter Life Sciences Partners with Automata to Accelerate AI-Ready Laboratory Automation

Refeyn logo

Refeyn named in the Sunday Times 100 Tech list of the UK’s fastest-growing technology companies